Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL): Inpatient and Outpatient Settings

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
A retrospective, non-interventional cohort study was used to address the study objectives. This study aimed to provide a better understanding of real-world healthcare resource utilization (HRU) and healthcare reimbursement costs associated with chimeric antigen receptor modified T cell (CAR-T) therapy among patients with DLBCL.
Epistemonikos ID: 59f23f99b1c248b5b1483d48b98caf1aaf83326d
First added on: May 15, 2024